Skip to Main ContentSkip to FooterSkip to Search
Main menu
  1. Home
  2.  » 
  3. Catalent News
  4.  » Catalent Appoints Lisa Evoli Senior Vice President and Chief Human Resources Officer
RSS feed icon

Catalent Appoints Lisa Evoli Senior Vice President and Chief Human Resources Officer

SOMERSET, N.J. — Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that Lisa Evoli has been named Senior Vice President & Chief Human Resources Officer, effective immediately.

Ms. Evoli joins Catalent from Integra Lifesciences, a global medical technology company based in Princeton, New Jersey.

“Lisa is a proven leader with more than 25 years of experience achieving organizational results, building robust talent pipelines, and creating an inclusive and engaged workforce for a variety of multinational public companies,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “Her deep health industry knowledge will be highly valuable as we continue to strengthen and support Catalent’s world-class workforce to create value for all our stakeholders.”

Prior to her tenure at Integra Lifesciences, Ms. Evoli held senior leadership roles at TE Connectivity, Johnson & Johnson, and Motorola. She holds a bachelor’s degree in business administration from California University of Pennsylvania and a master’s degree in human resources development from Villanova University.

She will be responsible for leading Catalent’s global human resources strategy, including talent acquisition, leadership development, diversity and inclusion, organizational design, compensation and benefits, HR operations and technology, and performance management.

Ms. Evoli replaces Ricardo Pravda, who will assume the role of Chief Transformation Officer. As part of this new role, Mr. Pravda will assist with the Human Resources aspects of Catalent’s ongoing network portfolio review, which will enable the company to unlock incremental value and require senior executive engagement across the company.




Catalent, Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information


More products. Better treatments. Reliably supplied.™